2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

[1]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[2]  E. Amsterdam,et al.  Management of ST-segment elevation myocardial infarction in EDs. , 2008, The American journal of emergency medicine.

[3]  E. Antman,et al.  Development of Systems of Care for ST-Elevation Myocardial Infarction Patients , 2007 .

[4]  B. Lewis,et al.  Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. , 2007, Journal of the American College of Cardiology.

[5]  A. Parkhomenko,et al.  Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. , 2007, European heart journal.

[6]  E. Antman,et al.  Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. , 2007, European heart journal.

[7]  M. Al-mallah,et al.  The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials. , 2007, American heart journal.

[8]  E. Antman,et al.  Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.

[9]  E. Vicaut,et al.  Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. , 2007, European heart journal.

[10]  J. Tu,et al.  Clinical ResearchInterventional CardiologyRescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis of Randomized Trials , 2007 .

[11]  J. Sluijter,et al.  Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig , 2007, Circulation.

[12]  G. Lamas,et al.  Coronary intervention for persistent occlusion after myocardial infarction. , 2006, The New England journal of medicine.

[13]  G. Lamas,et al.  Randomized Trial of Percutaneous Coronary Intervention for Subacute Infarct-Related Coronary Artery Occlusion to Achieve Long-Term Patency and Improve Ventricular Function: The Total Occlusion Study of Canada (TOSCA)–2 Trial , 2006, Circulation.

[14]  Harlan M Krumholz,et al.  Strategies for reducing the door-to-balloon time in acute myocardial infarction. , 2006, The New England journal of medicine.

[15]  David P Miller,et al.  Hospital Delays in Reperfusion for ST-Elevation Myocardial Infarction: Implications When Selecting a Reperfusion Strategy , 2006, Circulation.

[16]  S. Yusuf,et al.  Abstract 3296: Effects of Fondaparinux in Patients with ST-Segment Elevation Acute Myocardial Infarction Non-Eligible for Reperfusion Treatment , 2006 .

[17]  E. Antman,et al.  Abstract 3288: Association of Treatment with Non-Steroidal Anti-Inflammatory Agents (NSAIDS) on Study Entry with 30 Day Adverse Outcomes Among ST Elevation MI (STEMI) Patients Treated with a Fibrinolytic Agent. An EXTRACT-TIMI 25 Analysis , 2006 .

[18]  S. Yusuf,et al.  Abstract 3294: Fondaparinux versus Control (Placebo or Unfractionated Heparin) as an Adjunct to Thrombolytic Therapy in Acute Myocardial Infarction: an OASIS 6 Substudy , 2006 .

[19]  P. McGettigan,et al.  Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. , 2006, JAMA.

[20]  G. Montalescot,et al.  Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. , 2006, Journal of the American College of Cardiology.

[21]  R. Giugliano,et al.  The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study. , 2006, Journal of the American College of Cardiology.

[22]  L. Køber,et al.  Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction , 2006, Circulation.

[23]  S. Ellis,et al.  A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis. , 2006, The American journal of cardiology.

[24]  J. Emberson,et al.  Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.

[25]  M. Pfeffer,et al.  AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. , 2006, Journal of the American College of Cardiology.

[26]  S. Lagakos.  The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.

[27]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[28]  Harlan M Krumholz,et al.  The pre-hospital electrocardiogram and time to reperfusion in patients with acute myocardial infarction, 2000-2002: findings from the National Registry of Myocardial Infarction-4. , 2006, Journal of the American College of Cardiology.

[29]  E. Antman,et al.  Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. , 2006, The New England journal of medicine.

[30]  Salim Yusuf,et al.  Comparison of fondaparinux and enoxaparin in acute coronary syndromes. , 2006, The New England journal of medicine.

[31]  S. Yusuf,et al.  Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. , 2006, JAMA.

[32]  M. Leoncini,et al.  Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. , 2006, International journal of cardiology.

[33]  J. Boura,et al.  Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials , 2006, The Lancet.

[34]  Mary M Hand,et al.  Pre-hospital 12-lead electrocardiography programs: a call for implementation by emergency medical services systems providing advanced life support--National Heart Attack Alert Program (NHAAP) Coordinating Committee; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health. , 2006, Journal of the American College of Cardiology.

[35]  P. Armstrong,et al.  Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial , 2006, The Lancet.

[36]  H. Krumholz,et al.  Relation Between Hospital Specialization With Primary Percutaneous Coronary Intervention and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction: National Registry of Myocardial Infarction-4 Analysis , 2006, Circulation.

[37]  W. Frishman.  Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 AnalysisNallamothu BK, for the NRMI Investigators (Ann Arbor VA Med Ctr, Mich; et al) Circulation 111:761–767, 2005§ , 2006 .

[38]  S. Stevens,et al.  Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. , 2005, The New England journal of medicine.

[39]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[40]  R. Collins,et al.  Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[41]  R. Califf,et al.  Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.

[42]  G. Lamas,et al.  Design and methodology of the Occluded Artery Trial (OAT). , 2005, American heart journal.

[43]  R. Schiele,et al.  Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. , 2005, European heart journal.

[44]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[45]  Barbara T. Unger,et al.  Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. , 2005, American heart journal.

[46]  Advance Mi Investigators.  Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. , 2005, American heart journal.

[47]  Philip Greenland,et al.  The use of nonsteroidal anti-inflammatory drugs (NSAIDs): a science advisory from the American Heart Association. , 2005, Circulation.

[48]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[49]  Harlan M Krumholz,et al.  Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 Analysis , 2005, Circulation.

[50]  E. Antman,et al.  Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.

[51]  S. Yusuf,et al.  Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. , 2005, JAMA.

[52]  P. Rothwell.  Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.

[53]  K. Swedberg,et al.  [Expert Consensus document on beta-adrenergic receptor blockers]. , 2004, Revista espanola de cardiologia.

[54]  G. Gross,et al.  Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. , 2005, American heart journal.

[55]  K. Huber,et al.  Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. , 2004, European heart journal.

[56]  R. Porcher,et al.  DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. , 2004, European heart journal.

[57]  Lippincott Williams Wilkins,et al.  ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[58]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[59]  M. de Belder,et al.  A randomized trial of rescue angioplasty versus a conservative approach for failed fibrinolysis in ST-segment elevation myocardial infarction: the Middlesbrough Early Revascularization to Limit INfarction (MERLIN) trial. , 2004, Journal of the American College of Cardiology.

[60]  S. Nekolla,et al.  Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. , 2004, JAMA.

[61]  H. Suryapranata,et al.  Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. , 2004, European heart journal.

[62]  F. Fernández‐Avilés,et al.  1118-78 Primary angioplasty versus facilitated intervention (tenecteplase plus stenting) in patients with ST elevated acute myocardial infarction: Final results of the GRACIA-2 trial , 2004 .

[63]  D. Cutlip,et al.  Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. , 2003, The American journal of cardiology.

[64]  M. Dalby,et al.  Transfer for Primary Angioplasty Versus Immediate Thrombolysis in Acute Myocardial Infarction: A Meta-Analysis , 2003, Circulation.

[65]  P. Armstrong,et al.  Efficacy and Safety of Tenecteplase in Combination With the Low-Molecular-Weight Heparin Enoxaparin or Unfractionated Heparin in the Prehospital Setting: The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS Randomized Trial in Acute Myocardial Infarction , 2003, Circulation.

[66]  E. Antman,et al.  American College of Cardiology/American Heart Association clinical practice guidelines: Part I: where do they come from? , 2003, Circulation.

[67]  E. Antman,et al.  Fibrinolysis for acute myocardial infarction: the future is here and now. , 2003, Circulation.

[68]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[69]  A. Yeung,et al.  Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial , 2003, Circulation.

[70]  H. Arntz.  P1502 Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study , 2003 .

[71]  H. Gabriel.  P2853 Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI Frame Count: results of the ERAMI trial , 2003 .

[72]  J. Mattson,et al.  Delayed-Onset Heparin-Induced Thrombocytopenia , 2002, Annals of Internal Medicine.

[73]  M. Noc,et al.  Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. , 2002, The American journal of cardiology.

[74]  H. White.  Further evidence that antithrombotic therapy is beneficial with streptokinase: improved early ST resolution and late patency with enoxaparin. , 2002, European heart journal.

[75]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[76]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[77]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[78]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[79]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[80]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[81]  H. Suryapranata,et al.  Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. , 2000, European heart journal.

[82]  S. Assmann,et al.  Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.

[83]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial , 1999 .

[84]  W. Dassen,et al.  Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study , 1999, Heart.

[85]  S. Greenhouse,et al.  A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. , 1999, Journal of the American College of Cardiology.

[86]  N Freemantle,et al.  beta Blockade after myocardial infarction: systematic review and meta regression analysis. , 1999, BMJ.

[87]  K. Lee,et al.  Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. , 1998, Journal of the American College of Cardiology.

[88]  E. Bates.  Revisiting reperfusion therapy in inferior myocardial infarction. , 1997, Journal of the American College of Cardiology.

[89]  R. Collins,et al.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. , 1997, The New England journal of medicine.

[90]  J. Hirsh,et al.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. , 1995, The New England journal of medicine.

[91]  E. Topol,et al.  Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute anterior myocardial infarction. , 1994, Circulation.

[92]  S. Nightingale.  Appropriate Use of Low-Molecular-Weight Heparins (LMWHs) , 1993 .

[93]  F. Van de Werf,et al.  Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy. , 1993, Journal of the American College of Cardiology.

[94]  W. O’Neill,et al.  A Prospective, Placebo‐Controlled, Randomized Trial of Intravenous Streptokinase and Angioplasty Versus Lone Angioplasty Therapy of Acute Myocardial Infarction , 1992, Circulation.

[95]  D. Waters,et al.  Reactivation of unstable angina after the discontinuation of heparin. , 1992, The New England journal of medicine.

[96]  I. Belenkie,et al.  Rescue angioplasty during myocardial infarction has a beneficial effect on mortality: a tenable hypothesis. , 1992, The Canadian journal of cardiology.

[97]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[98]  A. Tonkin,et al.  A Randomized Comparison of Intravenous Heparin With Oral Aspirin and Dipyridamole 24 Hours After Recombinant Tissue‐Type Plasminogen Activator for Acute Myocardial Infarction , 1991, Circulation.

[99]  W. Rogers,et al.  Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. , 1991, Circulation.

[100]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.